<DOC>
	<DOC>NCT00106353</DOC>
	<brief_summary>This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity. (recruiting)</brief_summary>
	<brief_title>Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Part 1 only: Subjects with a histological diagnosis of advanced cancer (solid tumors or central nervous system [CNS] tumors) with disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available (histological confirmation waived for brain stem gliomas and optic pathway tumors) Part 2 only: Subjects with histologically confirmed diagnosis of refractory or relapsed: Neuroblastoma, Highgrade gliomas: glioblastoma multiforme, anaplastic astrocytomas, and other highgrade gliomas (histological confirmation waived for brain stem gliomas), Rhabdomyosarcoma. Measurable disease (for subjects with neuroblastoma, evaluable disease as determined by a positive metaiodobenzylguanidine (MIBG) scan will also be permitted). Subjects receiving enzymeinducing anticonvulsants. Pulmonary hypertension or pneumonitis Active infection or serious intercurrent illness Other exclusions apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pediatric Tumors</keyword>
</DOC>